



European Patent
Office

**SUPPLEMENTARY
PARTIAL EUROPEAN SEARCH REPORT**

Application Number

which under Rule 45 of the European Patent Convention EP 02 72 1608 shall be considered, for the purposes of subsequent proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Y	DATABASE EMBL [Online] 30 June 1999 (1999-06-30), "Homo sapiens esophageal cancer susceptibility protein (ECRG1) mRNA, complete cds." XP002312706 retrieved from EBI accession no. EM_HUM:AF071882 Database accession no. AF071882 The sequence has 98.8% identity with SEQ ID NO: 5 over the whole range(in the region from nt 610 to 1365) -----	1-109	C12N9/64 C12N15/57 C12N15/74 C12N15/79 C12Q1/37
P,Y	WO 01/36645 A (BURGESS CATHERINE ; QUINN KERRY E (US); RASTELLI LUCA (US); VERNET COR) 25 May 2001 (2001-05-25) SEQ ID NO: 11 (Ser5) has 80.5% identity with SEQ ID NO: 18 over the whole range ----- -/--	1-109	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C12N
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
INCOMPLETE SEARCH			
The Search Division considers that the present application, or some or all of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for the following claims: Claims searched completely : Claims searched incompletely : Claims not searched : Reason for the limitation of the search: see sheet C			
Place of search		Date of completion of the search	Examiner
Munich		7 January 2005	Grosskopf, R
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

1
EPO FORM 1503 06.02 (P04C20)



DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
P,Y	<p>DATABASE Geneseq [Online] 7 November 2001 (2001-11-07), "Human cDNA encoding a novel secreted protein, SEQ ID 69." XP002312707 retrieved from EBI accession no. GSN:AAS26877 Database accession no. AAS26877 The sequence has 99.4% identity with SEQ ID NO: 5 over the whole range (corresponds to nt 500 to 1277 of SEQ ID NO: 69 of W00155441) & WO 01/55441 A (HUMAN GENOME SCIENCES INC ; ROSEN CRAIG A (US); BARASH STEVEN C (US);) 2 August 2001 (2001-08-02) -----</p>	1-109	<p>TECHNICAL FIELDS SEARCHED (Int.Cl.7)</p>



Although claims 99-102 are directed to a diagnostic method practised on the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.

Claim(s) searched incompletely:

3,7-13,21-22,24-36,38-42,50-82,87-102,104-108

Claim(s) not searched:

1,2,4-6,14-20,23,37,43-49,83-86,103,109

Reason for the limitation of the search:

The reasons for not carrying out a search for the claims mentioned above are as follows:

In Claims 1,2,4-6,20 and 37 the claimed entity or the essential part of the claim is merely defined by an arbitrary designation which makes a meaningful search impossible.

The same, in principle applies with regard to Claims 14 and 103 where the claimed protein is merely defined by 3 consecutive amino acids.

Claims 15-19 and 23 relate to muteins of the specific protein which should have a certain minimum activity.

However, the possible structural variations are so broad and no region to be modified is indicated, so that a meaningful search is not possible.

Claims 43-48 and 109 relate to antisense, dsRNA, probes or antibodies directed to nucleic acids or proteins defined in previous claims.

However, due to the high degree of variation which is already introduced in said previous claims (per cent identity, hybridising) it is impossible to carry out a search for fragments, antisense RNA pieces or antibodies directed against said accordingly defined nucleic acids or proteins.

Claims 56-58 and 83-92 relate to "combinations comprising" or the "use of" inhibitors of the polypeptides as previously defined. However, the inhibitors themselves are not characterised by any meaningful technical feature which would allow a search for them.

As far as the remaining claims are concerned, and in view of the observations above, they have only been searched insofar as they relate to specifically and clearly defined proteins or nucleic acids.

In view of the impossibility to search the above defined embodiments, an explicit objection for lack of unity has not been raised in this stage of the procedure, which certainly applies when considering the prior art.

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 72 1608

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

07-01-2005

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0136645 A	25-05-2001	AU 1777901 A	30-05-2001
		CA 2391908 A1	25-05-2001
		EP 1244793 A2	02-10-2002
		JP 2003533174 T	11-11-2003
		WO 0136645 A2	25-05-2001
		US 2003077697 A1	24-04-2003

WO 0155441 A	02-08-2001	AU 2950801 A	07-08-2001
		AU 3095801 A	07-08-2001
		AU 3645901 A	07-08-2001
		AU 3646001 A	07-08-2001
		AU 3646101 A	07-08-2001
		AU 3646201 A	07-08-2001
		AU 3646301 A	07-08-2001
		AU 3646401 A	07-08-2001
		AU 3646501 A	07-08-2001
		AU 3646601 A	07-08-2001
		AU 3794301 A	07-08-2001
		AU 3794401 A	07-08-2001
		AU 3794701 A	07-08-2001
		AU 3794901 A	07-08-2001
		AU 3795001 A	07-08-2001
		AU 3795101 A	07-08-2001
		AU 3795201 A	07-08-2001
		AU 3795301 A	07-08-2001
		AU 3795401 A	07-08-2001
		AU 3795501 A	07-08-2001
		AU 3795701 A	07-08-2001
		AU 3795801 A	07-08-2001
		AU 3972601 A	07-08-2001
		AU 3972701 A	07-08-2001
		AU 3972801 A	07-08-2001
		AU 4140201 A	07-08-2001
		AU 4140301 A	07-08-2001
AU 4140401 A	07-08-2001		
AU 4140501 A	07-08-2001		
AU 4140601 A	07-08-2001		
AU 4140701 A	07-08-2001		
AU 4140801 A	07-08-2001		
AU 4140901 A	07-08-2001		
AU 4141001 A	07-08-2001		
AU 4141101 A	20-08-2001		
AU 4141201 A	07-08-2001		
AU 4141301 A	07-08-2001		
AU 4141401 A	07-08-2001		
AU 4141501 A	07-08-2001		

EPO FORM P0458

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 72 1608

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

07-01-2005

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0155441 A		AU 4141601 A	07-08-2001
		AU 4141701 A	07-08-2001
		AU 4141801 A	07-08-2001
		AU 4141901 A	07-08-2001
		AU 4313401 A	07-08-2001
		AU 4313501 A	07-08-2001
		AU 4313601 A	07-08-2001
		AU 4313701 A	14-08-2001
		AU 4526201 A	07-08-2001
		AU 4719001 A	07-08-2001
		AU 4719101 A	07-08-2001

专利名称(译)	编码跨膜蛋白丝氨酸蛋白酶9的核酸分子，编码的多肽和基于其的方法		
公开(公告)号	EP1379637A4	公开(公告)日	2005-04-06
申请号	EP2002721608	申请日	2002-03-27
[标]申请(专利权)人(译)	Dendreon公司圣迭戈		
申请(专利权)人(译)	Dendreon公司圣迭戈LLC		
当前申请(专利权)人(译)	Dendreon公司圣迭戈LLC		
[标]发明人	MADISON EDWIN L ONG EDGAR O		
发明人	MADISON, EDWIN, L. ONG, EDGAR, O.		
IPC分类号	A01K67/027 A61K31/7088 A61K31/7105 A61K39/395 A61K45/00 A61K48/00 A61P35/00 A61P43/00 C07K16/40 C12M1/00 C12N1/19 C12N1/21 C12N5/10 C12N9/64 C12N11/08 C12N15/09 C12N15/57 C12P21/08 C12Q1/37 C12R1/84 G01N33/15 G01N33/50 G01N33/53 G01N33/566 C12N15/74 C12N15/79		
CPC分类号	A61P35/00 A61P43/00 C12N9/6424 Y10S436/809		
优先权	60/279228 2001-03-27 US 60/291501 2001-05-15 US		
其他公开文献	EP1379637A2		
外部链接	Espacenet		

摘要(译)

本文提供II型跨膜丝氨酸蛋白酶9 (MTSP9) 多肽。还提供了酶原和这些多肽的活化形式以及蛋白酶结构域的单链和双链形式。提供了使用多肽鉴定调节MTSP9的蛋白酶活性的化合物的方法。

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Y	DATABASE EMBL [Online] 30 June 1998 (1999-06-30), "Homo sapiens esophageal cancer susceptibility protein (ESOP1) mRNA, complete cds." XP002312706 Retrieved from EBI accession no. EM_HUM:AF071882 Database accession no. AF071882 The sequence has 98.8% identity with SEQ ID NO: 5 over the whole range (in the region from nt 610 to 1365).	1-109	C12N9/64 C12N15/57 C12N15/74 C12N15/79 C12Q1/37
P, Y	WO 01/36645 A (BURGESS CATHERINE ; QUINN KERRY E (US); RASTELLI LUCA (US); VERNET COR) 25 May 2001 (2001-05-25) SEQ ID NO: 11 (Ser5) has 80.5% identity with SEQ ID NO: 18 over the whole range ----- -/-	1-109	TECHNICAL FIELDS SEARCHED (Int.Cl.7) C12N
The supplementary search report has been based on the last set of claims valid and available at the date of the search.			
INCOMPLETE SEARCH			
The Search Division considers that the present application, or some or all of its claims, should not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for the following reasons: Claims searched completely: Claims not searched: Reason for the limitation of the search: see sheet C			
1	Place of search Munich	Date of completion of the search 7 January 2005	Searcher Grosskopf, R
CATEGORY OF CITED DOCUMENTS		I: theory or principle underlying the invention E: earlier published documents, for publication, or after the filing date D: document cited in the application C: document cited for other reasons A: technical background P: prior art document I: intermediate document	